Terapias Dirigidas para la Oncología de Precisión

Home
Investigación
Cáncer
Terapias Dirigidas para la Oncología de Precisión

Publicaciones

2026

Bernardo, S, Brunet, L, Thomas, QD, Bracquemond, D, Bouclier, C, Colomb, M, Mancini, M, Fabbrizio, E, Santos, A, Rasamizafy, SF, Maacha, AM, Giry, A, Bousquet-Mur, E, Papon, L, Goussard, M, Fremin, C, Pasquier, A, Rodríguez, M, Travert, C, Pujol, JL, Linares, LK, Heron-Milhavet, L, Djiane, A, Ferrer, I, Paz-Ares, L, Quantin, X, Montuenga, LM, Tourriere, H, Maraver, A (2026).

NOTCH1 intracellular domain stabilization by MDM2 plays a major role in NSCLC response to platinum

EMBO Molecular Medicine. Article. 18(2):514-541.
[doi:10.1038/s44321-025-00354-9]

2025

Ballesteros-González, I, Hernández-Navas, I, Brehey, O, Lechuga, CG, Salmon, M, Scotece, M, Velasco-Vicente, R, Flores-Gomez, AA, Cebriá, A, Simon-Carrasco, L, Jiménez, G, Musteanu, M, Guerra, C, Domínguez, O, Caleiras, E, Blanco-Aparicio, C, Pons, T, Ferrer, I, Paz-Ares, L, Torres-Ruiz, R, Rodríguez-Perales, S, Barbacid, M, Drosten, M (2025).

The repressor Capicua is a barrier to lung tumor development driven by Kras/Trp53 mutations

EMBO Molecular Medicine. Article. 17(12):3377-3406.
[doi:10.1038/s44321-025-00326-z]

Otero-Rosales, M, Alvarez-González, M, Pazos, I, de Luxán-Delgado, B, Del Marro, S, Pozo-Agundo, E, Rodríguez-Santamaría, M, López-Fernández, A, Corte-Torres, D, Granda-Díaz, R, Alvarez-Teijeiro, S, Fernández-Vega, I, Lorz, C, García-Escudero, R, Rodrigo, JP, Tzelepis, K, Vassiliou, G, Ferrer, I, Alvarez-Fernández, M, García-Pedrero, JM, Hermida-Prado, F (2025).

CDK7-targeted therapy effectively disrupts cell cycle progression and oncogenic signaling in head and neck cancer

Signal Transduction and Targeted Therapy. Article. 10(1).
[doi:10.1038/s41392-025-02452-z]

Redin, E, Otegui, N, Santos, M, Leon, S, Redrado, M, Serrano, D, de Pierola, EF, Russo-Cabrera, JS, Ferrer, I, Olmedo, M, Diaz-Lagares, A, Houry, M, Vicent, S, Vilalta, A, Mondelo-Macía, P, García-González, J, León-Mateos, L, Gonzalez, A, Paz-Ares, L, López, R, Sanmamed, MF, Montuenga, L, Calvo, A (2025).

Dasatinib Remodels the Tumor Microenvironment and Sensitizes Small Cell Lung Cancer to Immunotherapy

CANCER RESEARCH. Article. 85(20):3910-3929.
[doi:10.1158/0008-5472.CAN-24-2772]

Alvarez-Perez, JC, Sanjuán-Hidalgo, J, Arenas, AM, Hernández-Navas, I, Benitez-Cantos, MS, Andrades, A, Calabuig-Fariñas, S, Jantus-Lewintre, E, Paz-Ares, L, Ferrer, I, Medina, PP (2025).

High-fidelity Cas9-mediated targeting of KRAS driver mutations restrains lung cancer in preclinical models

Nature Communications. Article. 16(1).
[doi:10.1038/s41467-025-62350-4]

Cirauqui, C, Ojeda, L, Otano, I, Pazos, I, Santos, A, Garrido-Martín, EM, Yagüe, P, Ramos-Paradas, J, Molina-Pinelo, S, Roncador, G, Solórzano, JL, Muñoz, MT, Cozar, P, Plaza, P, Suárez, R, Jiménez, M, Moreno, R, Rosado, A, Gámez, P, García-Luján, R, Zugazagoitia, J, Sweet-Cordero, EA, Barbacid, M, Carnero, A, Ferrer, I, Paz-Ares, L (2025).

Interleukin-11 promotes lung adenocarcinoma tumourigenesis and immune evasion

Clinical and Translational Medicine. Article. 15(7).
[doi:10.1002/ctm2.70374]

2024

Jiménez-Reinoso, A, Molero-Abraham, M, Cirauqui, C, Blanco, B, Garrido-Martin, EM, Nehme-Alvarez, D, Domínguez-Alonso, C, Ramírez-Fernández, A, Díez-Alonso, L, Nuñez-Buiza, A, González-Murillo, A, Tobes, R, Pareja, E, Ramírez-Orellana, M, Rodriguez-Peralto, JL, Ferrer, I, Zugazagoitia, J, Paz-Ares, L, Alvarez-Vallina, L (2024).

CD4⁺ tumor-infiltrating lymphocytes secreting T cell-engagers induce regression of autologous patient-derived non-small cell lung cancer xenografts

OncoImmunology. Article. 13(1):2392897-2392897.
[doi:10.1080/2162402X.2024.2392897]

Molina-Pinelo S, Ferrer Sánchez I, Najarro P, Paz-Ares L, Fernández L, Castelló N, Richart López LA, Rodríguez Gambarte JD, Sanz García M, Salinas A, Suárez R, Romero-Romero B, Martín-Juan J, Viñuela ME, Butler RG, de Pedro N (2024).

Telomere-based risk models for the early diagnosis of lung cancer.

Heliyon. Article. 10(24):41040-41040.
[doi:10.1016/j.heliyon.2024.e41040]

Sánchez-Ortega M, Garrido A, Cirauqui C, Sanz-Gonzalez L, Hernández MC, González-García A, Obregon K, Ferrer I, Paz-Ares L, Carrera AC (2024).

A potential therapeutic strategy based on acute oxidative stress induction for wild-type NRF2/KEAP1 lung squamous cell carcinoma.

Redox Biology. Article. 75:103305-103305.
[doi:10.1016/j.redox.2024.103305]

Figarol, S, Delahaye, C, Gence, R, Doussine, A, Cerapio, JP, Brachais, M, Tardy, C, Béry, N, Asslan, R, Colinge, J, Villemin, JP, Maraver, A, Ferrer, I, Paz-Ares, L, Kessler, L, Burrows, F, Lajoie-Mazenc, I, Dongay, V, Morin, C, Florent, A, Pagano, S, Taranchon-Clermont, E, Casanova, A, Pradines, A, Mazieres, J, Favre, G, Calvayrac, O (2024).

Farnesyltransferase inhibition overcomes oncogene-addicted non-small cell lung cancer adaptive resistance to targeted therapies

Nature Communications. Article. 15(1):5345-5345.
[doi:10.1038/s41467-024-49360-4]

2023

Macaya, I, Roman, M, Welch, C, Entrialgo-Cadierno, R, Salmon, M, Santos, A, Feliu, I, Kovalski, J, Lopez, I, Rodriguez-Remirez, M, Palomino-Echeverria, S, Lonfgren, SM, Ferrero, M, Calabuig, S, Ludwig, IA, Lara-Astiaso, D, Jantus-Lewintre, E, Guruceaga, E, Narayanan, S, Ponz-Sarvise, M, Pineda-Lucena, A, Lecanda, F, Ruggero, D, Khatri, P, Santamaria, E, Fernandez-Irigoyen, J, Ferrer, I, Paz-Ares, L, Drosten, M, Barbacid, M, Gil-Bazo, I, Vicent, S (2023).

Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer

Nature Communications. Article. 14(1).
[doi:10.1038/s41467-023-41828-z]

Ramos, AS, Sánchez, DG, Expósito, PP, Paz-Ares, L, Sánchez, IF (2023).

Understanding the basis for intrinsic resistance to KRASG12C inhibitors

ANNALS OF ONCOLOGY. Meeting Abstract. 34:753-753.
[doi:10.1016/j.annonc.2023.09.788]

Marrugal, A, Ferrer, I, Quintanal-Villalonga, A, Ojeda, L, Pastor, MD, García-Lujan, R, Carnero, A, Paz-Ares, L, Molina-Pinelo, S (2023).

Inhibition of HSP90 in Driver Oncogene-Defined Lung Adenocarcinoma Cell Lines: Key Proteins Underpinning Therapeutic Efficacy

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. Article. 24(18).
[doi:10.3390/ijms241813830]

Terapias Dirigidas para la Oncología de Precisión

Publicaciones

2026

NOTCH1 intracellular domain stabilization by MDM2 plays a major role in NSCLC response to platinum

2025

The repressor Capicua is a barrier to lung tumor development driven by Kras/Trp53 mutations

CDK7-targeted therapy effectively disrupts cell cycle progression and oncogenic signaling in head and neck cancer

Dasatinib Remodels the Tumor Microenvironment and Sensitizes Small Cell Lung Cancer to Immunotherapy

High-fidelity Cas9-mediated targeting of KRAS driver mutations restrains lung cancer in preclinical models

Interleukin-11 promotes lung adenocarcinoma tumourigenesis and immune evasion

2024

CD4+ tumor-infiltrating lymphocytes secreting T cell-engagers induce regression of autologous patient-derived non-small cell lung cancer xenografts

Telomere-based risk models for the early diagnosis of lung cancer.

A potential therapeutic strategy based on acute oxidative stress induction for wild-type NRF2/KEAP1 lung squamous cell carcinoma.

Farnesyltransferase inhibition overcomes oncogene-addicted non-small cell lung cancer adaptive resistance to targeted therapies

2023

Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer

Understanding the basis for intrinsic resistance to KRASG12C inhibitors

Inhibition of HSP90 in Driver Oncogene-Defined Lung Adenocarcinoma Cell Lines: Key Proteins Underpinning Therapeutic Efficacy

CD4⁺ tumor-infiltrating lymphocytes secreting T cell-engagers induce regression of autologous patient-derived non-small cell lung cancer xenografts